Biohaven Ltd. (BHVN) is in Healthcare, Biotechnology, based in United States, listed on NYSE. Market cap 1.80B USD. 52-week range 7.48 to 18.57 USD. Data as of 2026-10-09.
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 ...